Guidance for HIV sales growth increased to approximately 6% for 2026, up from prior expectations, while Yeztugo's revenue target increased markedly from $150 million to $800 million for the next year.
The biopharmaceutical company may start to offer two cancer therapies and an additional HIV treatment option this year.
Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2025.
Quarterly sales of HIV prevention drug Yeztugo, which was launched in the U.S. last year as a twice-yearly injection, totaled $96 million, beating the $88 million forecast by Wall Street, according ...
SHELTON, CONNECTICUT / ACCESS Newswire / February 10, 2026 / NanoViricides, Inc., a publicly traded company (NYSE ...
SHELTON, CONNECTICUT / ACCESS Newswire / February 2, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a ...
Fiji risks losing an entire generation to drugs if urgent action is delayed, church leaders and partners have warned, calling the growing crisis a threat to the nation’s survival.
In a federally funded clinical trial led by Johns Hopkins Medicine, people with tuberculosis infections (but not HIV) in two ...
Newborn screening will now be mandatory at birth, and children diagnosed with the disease will be followed up to manage ...
The Canadian Press on MSN
Oral HIV self-test approved for sale, advocates say it's key to elimination
TORONTO — ...
DENVER (AP) — Donovan Mitchell scored 32 points, including two free throws with 0.9 seconds left after James Harden's tying 3-pointer, and the Cleveland Cavaliers rallied to beat the Denver Nuggets ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results